Leclaza can be prescribed at general hospitals

Leclaza passed DC of 30 hospitals and clinics

Leclaza

Leclaza(Lazertinib Mesylate Monohydrate), a new domestic drug, is targeting the domestic lung cancer treatment market.

 

As more than 30 major medical institutions nationwide were able to prescribe in about eight months of domestic permission, it has entered the domestic market competition, which forms 150 billion won a year.

 

According to the industry on the 6th, Yuhan's Leclaza passed the drug committee of more than 30 medical institutions within two months of the launch of the benefit.

 

It can be prescribed at Seoul National University Hospital, Sinchon Severance Hospital, Samsung Medical Center, and Asan Medical Center, as well as upper-level general hospitals called "Big 4," National Cancer Center, Bundang Seoul National University Hospital, Seoul St.

 

Mary's Hospital, Hwasun Chonnam National University Hospital, Chilgok Kyungpook National University Hospital, and Pusan National University Hospital.

 

Leclaza became the 31st new drug to be developed in Korea with conditional approval from the MFDS on January 18 this year.

 

Patients with T790M-resistant local progressive or metastatic non-small cell lung cancer such as Iressa (Gefitinib), Tarceva(Erlotinib HCl), and Giotrif (Afatinib Dimaleate) are subject to administration.

 

It is a mechanism that inhibits the proliferation and growth of lung cancer cells by interfering with signaling involved in lung cancer cell growth.

 

Yuhan released it on July 1.

 

and applied for insurance registration on December 30 last year before the item license using the "Drug Approval-Patent Linkage System," and achieved high-speed registration 165 days after the license.

 

Despite its therapeutic effectiveness and safety comparable to AstraZeneca's Tagrisso (Osimertinib Mesylate), which acts as the same mechanism, it was recognized for its adequacy by offering low drug prices.

 

Academic organizations consisting of clinical specialists such as the Korean Cancer Study Group, The Korean Cancer Association, Korean Society of Medical Oncology, and Korean Association for Long Cancer also showed similar efficacy and safety to Tagrisso and had a low risk of heart toxicity.

 

It will be a new treatment alternative for patients with local progressive and metastatic non-small cell lung cancer with EGFR T790M mutations." EGFR mutation is a very common type of mutation observed in 30-40% of non-small cell lung cancers that account for 80-85% of lung cancer, occurring between exon No.

 

18 and 21.

 

It is known to be more prevalent in Asians.

 

EGFR-TKI, which can be prescribed in Korea until the release of Leclaza, is the first-generation drugs Iressa and Tarceva, Giotrif, Vizimpro, and Tagriso.

 

According to IQVIA, a pharmaceutical research institute, five EGFR-TKI types formed a market worth 74.3 billion won in the first half of this year.

 

Tagrisso, classified as a third-generation drug like Leclaza, accounts for 70% of the total market with 52 billion won in sales.

 

Based on the recommended daily dose, Leclaza's insurance upper limit is about 206,900 won.

 

It is about 10,000 won cheaper than Tagrisso (217,782 won).

 

An official from Yuhan said, "We are happy for Leclaza to pass the DC of major university hospitals and general hospitals nationwide at the same time as insurance benefits.With the start of Leclaza prescription in July, positive treatment effects are being derived from the treatment site." He said, "If more medical institutions can prescribe within this year, we will contribute to improving the unmet medical needs of cancer patients in Korea."